Navigation Links
PARP in Medical News

US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...ed to enroll more than 100 participants in this 420-patient study. Enrollment in the study opened July 16 in centers nationwide. "The BSI-201 parp Inhibitor is a potential game changing therapy in the treatment of triple-negative breast cancer. US Oncology Research is excited about the opportunit...

New Cancer Drug Fights Tumors in Those With BRCA Mutations

... protein involved in DNA repair. Healthy cells use parp to repair themselves, but cancer cells do the same...eam concluded. Iglehart thinks that combining a parp inhibitor with chemotherapy drugs that damage DNA ...over the cliff that would be only susceptible to a parp inhibitor," he said. In addition, "PARP inhibit...

BRIT1 allows DNA repair teams access to damaged sites

...ent Having shown that BRIT1 deficiency impairs HR repair, Peng said one solution the team is examining is to treat cancer cells lacking BRIT1 with parp inhibitors, drugs that specifically kill HR-deficient cancer cells. BRIT1 mutations are known to cause a neurological condition called primary micr...

New Insights, Inroads Against Breast, Ovarian Cancers

...esults with an entirely new class of drugs, called parp inhibitors -- the first targeted therapy for so-ca...eive chemo alone, the other half to chemo plus the parp inhibitor BSI-201. Those receiving the combina...pared with standard chemo. The second phase II parp inhibitor trial involved 54 women with advance bre...

Sanofi-aventis Announces Good First-quarter 2009 Performance

...ncology R&D portfolio with the addition of the parp inhibitor BSI-201 and demonstrating our strong com...lopment: -- BSI-201, a parp inhibitor, has entered our portfolio following ...could be a potential first-in-class parp inhibitor, and is currently in phas...

Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting

...uch as leukemia. Phase II trials for several tumor types began this year. parp Inhibitors (ABT-888) DNA damaging agents remain some of the most successf...caused by these agents used to treat cancer and render them ineffective. As parp activity is often increased in cancer cells, it provides these cells with a...

Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy

...ave a secondary mutation on their BRCA2 gene, their cancer likely would be resistant not only to platinum-based compounds but also other drugs such as parp inhibitors. Testing whether relapsed tumors have a secondary mutation of BRCA2 may be important to predict clinical outcome, Taniguchi said. The rese...

Americans Optimistic About the War on Cancer

...cientists from independent academic institutions and Abbott will present data on several of Abbott's investigational anti-cancer compounds including a parp inhibitor (ABT-888) that seeks to enhance the effectiveness of common cancer therapies, a multi-targeted kinase inhibitor (ABT-869) being investigated...

Astrazeneca's Investigational Cancer Therapies Revealed at ASCO

...s been studied in a range of tumor types in Phase I studies. The study presented today at ASCO showed that treatment with AZD2281 led to inhibition of parp functional activity in both surrogate and tumor tissue, and reported that strong signals were detected in hereditary ovarian cancer. Between 5% and 10...
PARP in Medical Technology

BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer

- Strategic Collaboration with the Gynecologic Oncology Group - BRISBANE, Calif., May 28 /PRNewswire/ -- BiPar Sciences, Inc. today announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial w...

BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting

- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors - BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data su...

BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data

BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast canc...

BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor

SAN FRANCISCO, Oct. 24 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced data demonstrating that BSI-401 inhibited pancreatic cancer cell growth in vitro and in vivo, both alone and in combination with oxaliplati...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has hired industry veterans Eric D. Malek as vice president of corporate development and Deborah A. Thomas as vice president fo...

Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was cond...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of cert...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...ed to enroll more than 100 participants in this 420-patient study. Enrollment in the study opened July 17 in centers nationwide. "The BSI-201 parp Inhibitor is a potential game changing therapy in the treatment of triple-negative breast cancer. US Oncology Research is excited about the opportunit...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

...o schedules and other ASCO information and resources, visit http://www.asco.org/presscenter . About BSI-201 Among other investigational parp inhibitors in the industry, BSI-201 is the furthest along in clinical development in metastatic TNBC. BSI-201 is currently being evaluated for its pot...

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer

... action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BSI-201 is the lead parp inhibitor program in Phase 2 clinical trials in multiple solid tumor settings. ...
PARP in Biological News

Mechanism identified for promising neurological drug

...inocycline turns out to be an extraordinarily good parp inhibitor, better than most of the drugs that are marketed as parp inhibitors," he says. The paper appears in the...to this time, we've been doing that with bona fide parp inhibitors. We intend now to look at minocycline i...
PARP in Biological Technology

A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage

Detection of early apoptotic events has become quite relevant since many studies have demonstrated that abnormalities in cell death regulation cause a variety of diseases and pathological conditions accompanied either b...

A DELFIA Assay for Inhibition of PARP

The DELFIA time-resolved fluorescence assay for inhibition of poly(ADP-ribose) polymerase (PARP) is a 96-well microplate assay that measures the inhibition of PARP-activated incorporation of biotinylated nicotinamide adenine diphsophate (NAD). The incorporation is detected using Europiuml...

Sanofi-aventis Announces Second Quarter 2009 Results

... the biotechnology company Exelixis SAR 407899, a rho-kinase inhibitor, entered Phase II in erectile dysfunction. BSI-201, a parp inhibitor, developed by BiPar Sciences (recently acquired by sanofi-aventis) entered Phase III in July. This pivotal study will evaluate the product i...

BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer

...o DNA repair that is upregulated in certain tumors. The company's lead compound, BSI-201, has entered a series of Phase 2 trials in tumors types where parp is overexpressed. The first of those trials will evaluate BSI-201 in patients with "triple negative" breast cancer, and BiPar expects to begin trials ...

Roche Diagnostics Corporation

...e Protein MIA as a Marker for Chondrocytes in Research Samples A Further Step in Understanding Apoptosis Direct Detection of parp Cleavage Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes ...
PARP in Biological Products

PARP Inhibitor XI, DR2313 from Calbiochem

Description:...M LIGHT. PACKAGED UNDER INERT GAS. A brain-permeable and water soluble pyrimidinone compound that acts as a potent and NAD + -competitive inhibitor of parp (IC 50 = 200 nM and 240 nM for rhPARP1 and rmPARP2, respectively) with little activity against the dehydrogenase activity of GAPDH, ADH, LDH, or the ...
Company:Calbiochem

PARP Cleavage Detection Kit from Calbiochem

Description:...e) polymerase (PARP) cleavage by Western blotting. parp is an enzyme implicated in DNA damage and repair mechanisms. During apoptosis, parp is cleaved by caspase-3. Cleavage of parp from the native 116 kDa to 85 kDa is a hallmark of...
Company:Calbiochem
Other Tags
(Date:8/27/2015)... Del. (PRWEB) , ... August 27, 2015 , ... Dr. ... will be the guest speaker at CURE® magazine’s 3rd Annual MPN Heroes™ recognition ... Dr. Arnold will be among hundreds of attendees honoring eight heroes who have made ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, ... Glushko, professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko ... her training and recovery. , With a focus on technology and comfort, Zensah® ...
(Date:8/27/2015)... ... August 27, 2015 , ... For the first time, Ninja® ... the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. These ... drink customization to a whole new level. This line of Nutri Ninja products ...
(Date:8/27/2015)... ... August 27, 2015 , ... Sunbelt® Bakery, maker of ... corn syrup, is changing the expectation of how protein bars should taste with the ... unlike any other protein bar on the market today. , The new Protein ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/19/2015)... 19, 2015  VOXX International Corporation (Nasdaq: ... into a Definitive Agreement to purchase the assets, ... market leader EyeLock through an acquiring entity.  Upon ... controlling interest in the acquiring entity. The closing ... due diligence.  Expanding on its existing supply chain ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
Other Contents